The effect of exenatide compared to insulin glargine on cardiac function and metabolism in type 2 diabetic patients with congestive heart failure: a randomized-controlled trial - CARDEXINE

Vrije Universiteit Medisch Centrum0 个研究点目标入组 62 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Patients:
•Type 2 diabetic patients
•Male and postmenopausal female
•Age 18 years and above
•Metformin therapy (stable, maximum tolerable dose for 2 months)
•HbA1c 6.5-10%
•Confirmed congestive heart failure (NYHA, functional class II-IV)
•Ejection Fraction (EF)<50%
•Stable standard therapy for their cardiac condition for 3 months prior to entering the study;- Healthy controls:
•Male and postmenopausal female
•Age 18 years and above
•No known acute or chronic disease

•- Patients:
•Type 1 diabetes
•Serious renal (creatinine clearance< 50 ml/min) or liver impairment
•(Receiving treatment for) malignant disease
•Cardiovascular event< 3 months prior to inclusion
•Acute congestive heart failure
•Any reason for not being able to sustain the imaging studies (impairment to understand the aim of the study/procedures, implanted devices, claustrophobia, atrial fibrillation, orthopnoe)
•Contraindications for the use of exenatide/insulin
•Use of insulin, thiazolidiones, (other than study) incretin-based therapies within 4 months of screening
•Chronic use of glucocorticoids, NSAIDs or centrally acting drugs (>2 weeks) within 2 weeks immediately prior to screening;- Healthy controls:
•Chronic use of any drug
•Impaired glucose tolerance (as assessed by a 75-g oral glucose tolerance test)

发起方